An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey

Centre Hospitalier Universitaire de Nīmes

Status: Completed

Conditions: Underdosing of Aminoglycosides; Critical Illness

Treatments: Other: Observational study, no intervention

Study type: Observational

Funder types: Other

Identifiers

NCT02850029

IRB 15 04 08

Details and patient eligibility

About

This is an international observational cohort study on current aminoglycoside practices in intensive care units. Clinical and demographic data, dosing and therapeutic drug monitoring data will be collected during the first week of aminoglycoside (tobramycin, amikacin or gentamicin) administration in different countries over a year. A minimum of ten consecutive patients will be enrolled at each site.

Full description

Aminoglycosides are commonly used antibiotics for difficult to treat infections. However, aminoglycoside administration varies widely among countries. The aim of this multicenter observational study is to provide up-to-date and comprehensive descriptive data on current aminoglycoside (tobramycin, amikacin or gentamicin) use in a large cohort of critically ill patients in different countries. The benefits expected from this study are a better understanding of worldwide aminoglycoside prescription variability in critically ill patients and to determine the risk factors of inadequate aminoglycoside dosing regimens.

Enrollment: 964 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years old
• Intensive care unit patients
• Receiving aminoglycoside therapy for a sepsis according to the Third International Consensus Definitions for Sepsis and Septic Shock

Exclusion criteria

• Aged < 18 years of age
• Previous inclusion in the study

Trial design

964 participants in 1 patient group

critically ill patients

Description:

Critically ill patients admitted in intensive care units and receiving one of the following aminoglycosides: gentamicin, tobramycin and amikacin as part of their usual care.

Treatment:

Other: Observational study, no intervention